Anacor Pharmaceuticals PT Raised to $24.00 (ANAC)
Investment analysts at Canaccord Genuity boosted their price target on shares of Anacor Pharmaceuticals (NASDAQ:ANAC) from $17.00 to $24.00 in a note issued to investors on Tuesday, Analyst Ratings Network.com reports. Canaccord Genuity’s price target would suggest a potential upside of 92.46% from the stock’s previous close.
Shares of Anacor Pharmaceuticals (NASDAQ:ANAC) opened at 12.47 on Tuesday. Anacor Pharmaceuticals has a 52-week low of $3.00 and a 52-week high of $11.76. The stock has a 50-day moving average of $9. and a 200-day moving average of $6.67. The company’s market cap is $505.8 million.
Anacor Pharmaceuticals (NASDAQ:ANAC) last announced its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $2.60 million. During the same quarter in the previous year, the company posted ($0.47) earnings per share. The company’s revenue for the quarter was up 30.8% on a year-over-year basis. Analysts expect that Anacor Pharmaceuticals will post $-1.65 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Wedbush raised their price target on shares of Anacor Pharmaceuticals from $20.00 to $29.00 in a research note to investors on Friday, October 18th. Analysts at Deutsche Bank raised their price target on shares of Anacor Pharmaceuticals from $11.00 to $20.00 in a research note to investors on Friday, October 18th. They now have a “buy” rating on the stock.
Anacor Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.